
SM-164
CAS No. 957135-43-2
SM-164 ( —— )
产品货号. M22507 CAS No. 957135-43-2
SM-164 与包含 BIR2 和 BIR3 结构域的 XIAP 蛋白结合 (IC50: 1.39 nM)。它是 XIAP 的极强拮抗剂。 SM-164 与 XIAP 的结合效力分别比其单价对应物和天然 Smac AVPI 肽强 300 倍和 7000 倍。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥1401 | 有现货 |
![]() ![]() |
5MG | ¥2341 | 有现货 |
![]() ![]() |
10MG | ¥3588 | 有现货 |
![]() ![]() |
25MG | ¥5816 | 有现货 |
![]() ![]() |
50MG | ¥8068 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称SM-164
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SM-164 与包含 BIR2 和 BIR3 结构域的 XIAP 蛋白结合 (IC50: 1.39 nM)。它是 XIAP 的极强拮抗剂。 SM-164 与 XIAP 的结合效力分别比其单价对应物和天然 Smac AVPI 肽强 300 倍和 7000 倍。
-
产品描述SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains (IC50: 1.39 nM). It acts as an extremely potent antagonist of XIAP. SM-164 binds to XIAP being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively. The binding affinities of SM-164 to XIAP, cIAP-1, and cIAP-2 proteins are determined using fluorescence-polarization based assays. SM-164 concurrently interacts with both BIR domains in XIAP and functions as an ultra-potent antagonist of XIAP in both cell-free functional and cell-based assays. SM-164 targets cellular XIAP and effectively induces apoptosis at concentrations as low as 1 nM in leukemia cancer cells while having minimal toxicity to normal human primary cells at 10,000 nM. SM-164 has a Ki value of 0.56 nM to XIAP protein containing both BIR2 and BIR3 domains. SM-164 has a Ki value of 0.31 nM to a cIAP-1 protein containing both BIR2 and BIR3 domains. SM-164 binds to cIAP-2 BIR3 protein with Ki values of 1.1 nM.SM-164 is highly effective in the inhibition of tumor growth and capable of achieving tumor regression in the MDA-MB-231 xenograft model. SM-164 (1 mg/kg) treatment fully inhibits tumor growth during the treatment. SM-164 (5 mg/kg) treatment reduces the tumor volume from 147±54 mm3 at the beginning of the treatment (day 25) to 54±32 mm3 at the end of the treatment (day 36), a reduction of 65%. The strong antitumor activity by SM-164 is long-lasting and not transient. SM-164 (5 mg/kg) is statistically more effective than Taxotere at the end of the treatment (P<0.01) or when the tumor size in the control group reached 750 mm3 (P<0.02).
-
体外实验——
-
体内实验——
-
同义词——
-
通路Apoptosis
-
靶点IAP
-
受体XIAP|cIAP-1|XIAP|cIAP-2|cIAP
-
研究领域——
-
适应症——
化学信息
-
CAS Number957135-43-2
-
分子量1121.42
-
分子式C62H84N14O6
-
纯度>98% (HPLC)
-
溶解度DMSO:5.2 mg/mL (4.64 mM; Need ultrasonic)
-
SMILES[H][C@]12CC[C@H](N1C(=O)[C@H](CCCC2)NC(=O)[C@H](C)NC)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@]4([H])CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94.